ReviewiScience2026
Selenium-catalyzed organic transformations.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium-catalyzed organic transformations have recently emerged as a promising frontier in modern organic synthesis. The unique combination of high polarizability, redox tunability, and σ-hole-driven Lewis acidity enables selenium to act as powerful non-covalent activators in both covalent and non-covalent catalytic cycles. These features allow organoselenium catalysts to stabilize transition states, facilitate bond activation, and deliver selectivity unattainable with traditional organocatalysts. Despite remarkable advances, the field remains in its infancy, hindered by mechanistic ambiguities, limited enantioselective control, and scalability challenges. This article summarizes recent progress in selenium-based organocatalysis with a special emphasis on chalcogen bonding, applications in synthesis, and evaluates the current limitations that impede large scale industrial adaptation by discussing existing challenges with perspectives for future industrial translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.